Udai S Kammula
UPMC Hillman Cancer Center · National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Udai S Kammula as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:10 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03935893 · Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid CancersUdai Kammula · active not recruiting · Gastric Cancer, Colorectal Cancer, Pancreatic Cancer · principal investigator
- Ph2NCT03801083 · Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract CancersUdai Kammula · active not recruiting · Biliary Tract Cancer, Cholangiocarcinoma, Biliary Tract Neoplasms · principal investigator
- Ph2NCT03467516 · Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal MelanomaUdai Kammula · active not recruiting · Uveal Neoplasms, Melanoma, Uveal · principal investigator
- Ph2NCT01495572 · Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor CellsNational Cancer Institute (NCI) · terminated · Metastatic Melanoma, Skin Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- High Throughput Isolation of Antigen Specific T-cells for Cancer TherapyZIABC010766 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2017 · $409,656 awarded in 2017Same name and institution; not confirmed by an ID
- Immunotherapy Strategies for Uveal MelanomaZIABC010649 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2017 · $409,656 awarded in 2017Same name and institution; not confirmed by an ID
- High Throughput Isolation of Antigen Specific T-cells for Cancer TherapyZ01BC010766 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2007 to 2008 · $421,954 awarded in 2008Same name and institution; not confirmed by an ID
- Immunotherapy Strategies for Gastrointestinal and Hepatocellular CancerZ01BC010649 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2005 to 2008 · $421,954 awarded in 2008Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:10 UTC. The ranking covers the 200 most relevant of 27 PubMed records, and a shared surname and initials can bring in a namesake. All 27 on PubMed
- 2,095 citationsRCR 39.8
- Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.Clin Cancer Res · 20111,739 citationsRCR 38.1
- Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.J Clin Oncol · 20111,338 citationsRCR 29.4
- 1,207 citationsRCR 28.9
- 1,151 citationsRCR 22.2
- Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.J Immunother · 20101,065 citationsRCR 22.3
- Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.J Immunother · 2013956 citationsRCR 23.3
- T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.Mol Ther · 2011834 citationsRCR 18.0
- Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.J Clin Oncol · 2005805 citationsRCR 14.9
- Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans.Cell Metab · 2014669 citationsRCR 22.2